~~<i id='84A18F7307'><strike id='84A18F7307'><tt id='84A18F7307'><pre id='84A18F7307'></pre></tt></strike></i>~~

Home» comprehensive» entertainment

entertainment

author：explore 2025-10-06 07:56:26 Page View：39995

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The stability of $0 premiums in Medicare Advantage
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

IVG is promising — but it won’t replace IVF quite yet

AdobeTherearetimeswhenanewmedicaltechnologyisthrustintothepublicspotlightbecauseitseemslikeitmightso

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

RSV injection headlines need to be accurate for good uptake

STAT/AstraZenecaviaAPAstheoristsfromSamuelColeridgetoKennethBurkehavenoted,languageoftendoesourthink